GSK Nears $1 Billion Deal for Biotech Company IDRx
GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...
GSK falls Thursday, underperforms market
Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...
GSK's Shingrix New Prefilled Syringe Presentation Accepted For Review By FDA
British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the ...
GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx
British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing ...
GSK application for new Shingrix formulation accepted by FDA
GSK announced on Friday that the US Food and Drug Administration (FDA) has accepted its regulatory application for a ...
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...
GSK rises Wednesday, outperforms market
GSK PLC GSK shares inched up 0.18% to £13.60 Wednesday, on what proved to be an all-around favorable trading session for the ...
FDA adds warning to RSV shots from GSK, Pfizer
Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
FiercePharma1d
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
Cure Today12h
FDA Grants BTD to the ADC GSK’227 in Relapsed/Refractory Osteosarcoma
The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...
GSK awaits FDA review of new shingles vaccine presentation
Shingrix in 2017 received US FDA approval to prevent shingles in adults aged 50 and older. Since 2021, it has been approved for use in immunocompromised patients aged 18 and up. GSK estimates around ...